\r\n\r\nOP0019 bimekizumab in patients with active ankylosing spondylitis: 24-week efficacy & safety from be mobile 2, a phase 3, multicentre, randomised, placebocontrolled study\r\n\r\n \r\n\r\nNavarro-Compán V, Rudwaleit M, de Peyrecave N et al. Maintenance of response to bimekizumab over 3 years of treatment in patients with active ankylosing spondylitis: post-hoc analyses from the BE AGILE study and its open-label extension. To be presented at EULAR 2022 in Copenhagen, Denmark, June 1-4\r\n\r\n","context":1,"show_related_articles":1,"related_title":"Relateret indhold","related_type":"automatic","author_title":"Forfatter"}}}; dataLayer.push( dataLayer_content ); \r\n\r\nPOS0939 bimekizumab in patients with active nonradiographic axial spondyloarthritis: 24-week efficacy & safety from be mobile 1, a phase 3, multicentre, randomised, placebo-controlled study\r\n\r\n \r\n\r\nOP0019 bimekizumab in patients with active ankylosing spondylitis: 24-week efficacy & safety from be mobile 2, a phase 3, multicentre, randomised, placebocontrolled study\r\n\r\n \r\n\r\nNavarro-Compán V, Rudwaleit M, de Peyrecave N et al. Maintenance of response to bimekizumab over 3 years of treatment in patients with active ankylosing spondylitis: post-hoc analyses from the BE AGILE study and its open-label extension. To be presented at EULAR 2022 in Copenhagen, Denmark, June 1-4\r\n\r\n","context":1,"show_related_articles":1,"related_title":"Relateret indhold","related_type":"automatic","author_title":"Forfatter"}}}; dataLayer.push( dataLayer_content );

Skip to Content

juni 2022

Bimekizumab viser positiv effekt over hele spektret af axial spondyloarthritis

Nye resultater fremlagt på dette års EULAR-kongres viser, at bimekizumab har vedvarende positiv effekt på hele spektret af axial spondyloarthritis (axSpA), herunder både non-radiografisk axSpA (nr-axSpA) og ankylosing spondylitis (AS).

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Få adgang
Hvis du allerede har en profil: Log ind

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen

Back to top